Mounjaro® uniquely mimics two incretin hormones, Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), enhancing its effectiveness in managing blood sugar levels. It is the first medication of its kind that acts on two receptors, promoting feelings of fullness by delaying gastric emptying and reducing glucagon production.